approval
saveDUPIXENT (DUPILUMAB) — FDA approval
community read0 votes
Sponsor: REGENERON PHARMACEUTICALS. Form: INJECTABLE. Route: INJECTION
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- phase 2 completionBrigham and Women's Hospital — dupilumab (Phase II Trial Completion)Apr 30, 2026 · 154d ago
- pdufaRegeneron Pharmaceuticals Inc — dupilumab (PDUFA)Apr 27, 2026 · 157d ago
- approvalDUPIXENT (DUPILUMAB) — FDA approvalFeb 23, 2026 · 220d ago
- approvalDUPIXENT (DUPILUMAB) — FDA approvalJun 18, 2025 · 470d ago
- approvalDUPIXENT (DUPILUMAB) — FDA approvalApr 17, 2025 · 532d ago
- approvalDUPIXENT (DUPILUMAB) — FDA approvalApr 16, 2025 · 533d ago
- approvalDUPIXENT (DUPILUMAB) — FDA approvalSep 27, 2024 · 734d ago
- approvalDUPIXENT (DUPILUMAB) — FDA approvalSep 12, 2024 · 749d ago
same company · ±60 days · 5
- pdufadupilumab: Regeneron Pharmaceuticals Inc — dupilumab (PDUFA)Apr 27, 2026
- earningsREGENERON PHARMACEUTICALS, INC. earningsApr 29, 2026
- approvalEYLEA HD: EYLEA HD (AFLIBERCEPT) — FDA approvalApr 2, 2026
- phase 2 completioncemiplimab: Regeneron Pharmaceuticals Inc — cemiplimab (Phase II Trial Completion)Apr 30, 2026
- approvaldupilumab: DUPIXENT (DUPILUMAB) — FDA approvalFeb 23, 2026
related news · 4
- oncliveCases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer
- statSTAT+: Pharmalittle: We’re reading about a Trump deal with Regeneron, reclassifying medical marijuana, and more
- biopharma diveFDA approves Regeneron’s hearing loss gene therapy
- biopharma diveSanofi posts upbeat sales as R&D pressure builds
comments(0)
5-min edit window · permanent after that